GLP-1 receptor agonists are the most consequential drug class to emerge in obesity and type-2 diabetes since metformin. The category started with exenatide and liraglutide, broke commercial ceilings with semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), and is now expanding into orals (orforglipron, oral semaglutide), triple agonists (retatrutide), and amylin combinations (cagrisema, eloralintide).
The signal worth tracking has shifted. Weight loss alone is no longer the headline — secondary indications are. SELECT showed a 20% drop in major adverse cardiovascular events for non-diabetic adults with obesity. A Mass General Brigham analysis in JAMA reported 42–58% lower heart-failure hospitalizations in HFpEF. AAN 2026 added migraine, dementia incidence, and Parkinson's signals to the growing list. The Phase 3 EVOKE Alzheimer's trial, by contrast, missed its endpoint.
Browse the latest below, or filter by drug at #semaglutide, #tirzepatide, #orforglipron, and #retatrutide.
A JAMA study led by a Yale researcher, reported by STAT on July 6, had an investigator pose as a patient across 49 websites selling branded or compounded semaglutide or tirzepatide between August and December 2025. Of those, 45 sites (91.8%) issued a prescription, with a median time to prescription of one day or less and often minimal clinical evaluation. The findings sharpen concerns about telehealth prescribing standards as enforcement against compounded GLP-1s tightens.
Anodyne Nanotech closed a $12.6 million Series A, led by Velocity Partners, to advance ANN-101, a once-weekly GLP-1 skin patch, into first-in-human trials. The Boston company's HeroPatch solid-state microneedle platform delivers multi-milligram doses of peptides without injections or cold storage, aiming to reach the drug exposures obesity treatment requires. The round adds to a wave of investment in alternatives to weekly GLP-1 injections.
The American College of Cardiology, American Heart Association, American Diabetes Association, and American Society of Nephrology jointly published the first-ever clinical guideline for Cardiovascular-Kidney-Metabolic (CKM) Syndrome on June 9, 2026, in Circulation and JACC. The framework establishes a standardized CKM staging system (stages 0 to 4) to identify patients earlier, personalize therapy by absolute cardiovascular risk, and promote both prevention and regression of disease. GLP-1 receptor agonists are explicitly recommended in select patients with type 2 diabetes or obesity plus other cardiovascular risk factors, alongside SGLT2 inhibitors and kidney-protective therapies. The guideline embeds the GLP-1 class into multi-society standard of care for the first time and adds clinical-society weight to the SELECT, FLOW, and ESSENCE outcomes evidence base.
A target trial emulation of more than 160,000 patients, published online June 7, 2026 in Annals of Oncology and presented at ASCO 2026, reported that adults with obesity but without diabetes who received GLP-1 receptor agonists had a 41% lower risk of obesity-associated cancers compared with non-users. Subgroup signals included a 68% reduction in men and a 58% reduction in endometrial cancer. Lead author Arthur Heng-Cheng Hsu (Houston Methodist Neal Cancer Center) and colleagues examined 13 obesity-associated cancers across the TriNetX nationwide database. The findings extend prior signals from the SELECT trial (cardiovascular benefit) and FLOW (kidney benefit) into oncology and add empirical weight behind the 21-expert global panel proposal for a 10-year prospective GLP-1 cancer-prevention trial first surfaced at ECO 2026 in Istanbul.
The Business Group on Health's June 2026 survey of 105 large US employers found 67% currently cover GLP-1 drugs for weight management, but about 10% of those covering plan to drop coverage in 2027 as total spending continues to climb even as per-unit GLP-1 prices have fallen. The Foundayo and Wegovy pill launches drew in patients who had not previously tried GLP-1 therapy, increasing aggregate utilization. Employers that continue covering are layering on management strategies: required participation in a weight-management program, biometric eligibility verification, and restricted prescribing to specific providers. The 2027 employer-coverage cliff is the next financial pressure point for Lilly, Novo, and the pharmacy benefit managers that have built obesity formularies around employer-sponsored plans.
A Stanford-led retrospective pre-post cohort study presented June 13 at ENDO 2026 in Chicago used NIH All of Us Research Program data linking electronic health records with Fitbit activity in 1,950 adults with obesity who started GLP-1 medications. Among the 753 with sufficient wearable data, mean daily steps dropped from 5,047 before GLP-1 initiation to 4,487 after (-560 steps, p<0.001); moderate-to-vigorous activity fell from 27.9 to 22.2 minutes per day (-5.7 minutes, p<0.001). The largest declines occurred in men and in people with pre-existing joint or muscle pain; age, heart failure, and stroke history did not change the pattern. Lead author Surya Maharjan flagged the activity drop as a concern given GLP-1-associated lean-mass loss.
A research team from University Hospitals Coventry and Warwickshire and Warwick Medical School presented meta-analysis data from randomized controlled trials at ENDO 2026 on June 14 showing that 24 weeks of GLP-1 receptor agonist treatment improved testosterone levels, sperm count, and sperm morphology in men ages 18 to 65 with obesity-related low testosterone. Principal investigator Pratibha Natesh proposed reduced inflammation and metabolic stress as candidate mechanisms, with the GLP-1 class potentially preferable to testosterone replacement therapy in this population because TRT can suppress endogenous sperm production. The findings were drawn from men with high BMI, so external validity to normal-weight populations is unclear.
AJMC reported real-world claims data showing that 51.3% of patients on GLP-1 drugs carry at least one diagnosis tied to an emerging GLP-1 indication, 13.8% carry two, and 6.8% carry three or more. Obstructive sleep apnea led the comorbidity prevalence at 25.5%, followed by major depressive disorder at 18.2%, chronic kidney disease at 10.6%, and NAFLD/NASH at 10.3%. The numbers quantify the indication creep the field has been narrating since ADA: prescribers are increasingly writing GLP-1s for patients whose secondary conditions align with the expanding regulatory map (Wegovy CV, FLOW kidney, SURMOUNT-OSA, ESSENCE MASH).
Novo Nordisk presented Phase 2 data for zenagamtide (formerly amycretin), its unimolecular GLP-1 and amylin receptor agonist, at ADA 2026 in 262 adults with type 2 diabetes randomized across six subcutaneous doses (0.4 to 40 mg) versus placebo. The 40 mg arm cut HbA1c by 1.71 percentage points and reduced body weight by 14.6% at 36 weeks, with nearly 89% of patients reaching HbA1c below 7%. The study met its primary HbA1c endpoint across all doses; Novo plans Phase 3 in H2 2026 and hosted a same-day R&D investor event.
5W Public Relations published the fourth installment of its AI Visibility Index, finding two manufacturers — Novo Nordisk and Eli Lilly — account for nearly 100% of GLP-1-class citations inside ChatGPT, Claude, Perplexity, and Google AI Overviews. Five products — Wegovy, Zepbound, Ozempic, Mounjaro, and Saxenda — capture about 57% of all weight-loss-and-metabolic-health category citations. Founder Ronn Torossian attributes the citation moat to peer-reviewed clinical data cadence, named-author editorial coverage, and regulatory events treated as content events, with content velocity outpacing the broader news cycle.
Prof. John Wilding (University of Liverpool) and colleagues will present at ECO 2026 a real-world observational study tracking obesity-linked complication rates by degree of GLP-1-driven weight loss. In the year following GLP-1 treatment initiation, 27.0% of patients had BMI reductions <5%, 22.4% had 5-<10%, 14.1% had 10-<15%, 15.8% had ≥15%, and 20.8% gained BMI. Over a mean 11-month follow-up, patients with ≥15% BMI reduction had 37% lower osteoarthritis odds, 30% lower CKD odds, 69% lower OSA odds, and 32% lower heart failure odds versus those with 0-5% reduction (all statistically significant except heart failure). Incidence per 1,000 person-years: 21.4 OA, 21.1 CKD, 20.3 OSA, 3.9 HF. The data quantifies the value of pushing for deeper weight loss rather than cruise-control dosing.
A Nature Communications umbrella review by Kong, Zhao, Zhang and colleagues synthesized 123 meta-analyses covering 464 outcomes from 5,617 articles to comprehensively assess GLP-1 receptor agonist effectiveness and adverse events across diverse outcomes. Outcomes were grouped into seven categories: endocrine and metabolic, cardiovascular, cancer, renal, respiratory, mortality and adverse events, and other. The review documented improvements in metabolic, cardiovascular, renal, and respiratory outcomes plus cognitive function, with potential reductions in fracture risk and all-cause mortality in selected populations. Increased risks were observed for diabetic retinopathy, ketoacidosis, gastrointestinal events, and treatment discontinuation — useful evidence-summary input for ECO 2026 in Istanbul (May 12–15) and the prevention-trial proposal that 21 obesity-and-cancer experts will present there.
Ahead of the European Congress on Obesity in Istanbul (May 12–15), a 21-expert global panel of obesity and cancer specialists will present a research proposal for a 10-year prospective trial testing GLP-1 receptor agonists like semaglutide and tirzepatide for prevention of obesity-related cancers. The proposal builds on the SELECT trial's established cardiovascular benefit, real-world dementia-incidence reductions, and the broader case that GLP-1s influence multiple aging-driven disease categories. The Istanbul meeting is the same venue where Novo Nordisk will present 52 abstracts on Wegovy, the higher-dose 7.2 mg formulation, the Wegovy pill, and CagriSema, including data on women's obesity, perimenopause, and migraine.
Novo Nordisk announced May 1 that Rybelsus is being retired as a US brand and the molecule re-launches Monday May 4 as Ozempic Pill at 1.5/4/9 mg in 70,000+ pharmacies. Bloomberg and Fierce Pharma framed it as a marketing-driven move: same active ingredient as Rybelsus, but reformulated for improved absorption and bioavailability so smaller tablets achieve equivalent efficacy. Aligning the oral and injectable products under a single brand is meant to simplify prior authorizations and prescribing discussions, and to capitalize on Ozempic's recognition as Novo defends market share against Lilly's Foundayo. Rybelsus continues outside the US.
DistilINFO and an Endocrine review published May 1 consolidated the clinical literature on accelerated facial aging in patients on GLP-1 receptor agonists. A 2025 Vanderbilt study reported approximately 9% midface volume loss per 10 kg of total weight loss, with GLP-1-mediated lipolysis disproportionately affecting superficial and medial cheek fat pads. The American Academy of Facial Plastic and Reconstructive Surgery reported a 50% increase in face-grafting procedures in the past year tied to the trend, and one in four surgeons expects continued growth in nonsurgical demand (fillers, microneedling, RF, CO2 laser). Mechanistic work in Endocrine adds a possible direct effect on adipose-derived stem cells beyond rapid fat loss alone.
The Partnership for Safe Medicines issued a May statement strongly supporting the FDA's April 30 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing-facility bulks list, citing 'sound science, sound law, and a clear-eyed commitment to patient safety.' The Partnership cited more than 455 adverse-event reports linked to compounded semaglutide and more than 320 tied to compounded tirzepatide — many involving dosing errors from multidose vials, some leading to hospitalization — as the safety basis. The group plans to submit a full comment to the Federal Register docket before the June 29 deadline and is encouraging other patient-safety groups to do the same.
Orrick published a May 2026 client memo walking through the FDA's April 30 proposal to formally exclude semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda) from the 503B outsourcing-facility bulk drug substances list. The memo flags that the FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved in February 2025, removing the two legal pathways that previously enabled large-scale compounding. Orrick advises weight-loss clinics, medical spas, and telehealth platforms still relying on compounded GLP-1 products to consult counsel ahead of the June 29 comment deadline.
Novo Nordisk announced May 1 that Ozempic (semaglutide) tablets at 1.5 mg, 4 mg, and 9 mg will be available across 70,000+ U.S. pharmacies starting Monday, May 4, for adults with type 2 diabetes. The product is the only FDA-approved oral peptide GLP-1 medication cleared for both primary and secondary cardiovascular risk reduction in adults with T2D, manufactured end-to-end in the United States. Insured patients can access the pill for as little as $25 for up to a 3-month supply; self-pay patients face $149–$299/month depending on dose strength.